“…27,32 Some expressed concerns about reduced vigilance or oversight of patients (Goldsamt, 2021), 33 or feared scrutiny of practices and outcomes by federal and state agencies . 31 Many expressed concerns about how take-home dosing would reduce revenue , Goldsamt, 2021, Hunter, 2021). 22,31,33,34 Some noted concerns around legal liability for potential overdose or diversion of methadone, which made them apprehensive about take-home dosing long-term , Hunter, 2021, Madden, 2021).…”